OBJECTIVE: Report the experience of the Karmanos Cancer Institute with sinonasal mucosal melanoma (SNMM) in patients diagnosed between 1995 and 2007. RESULTS: Eighteen patients, ages 31 to 85 (mean, 67), whose most common presenting symptoms included epistaxis and facial pressure. Most common anatomic locations were the maxillary sinus and nasal cavity. Seventy-two percent presented with tumors extending to the skull base, frontal sinus, orbit, or cranium. Tumor size ranged from 0.3 cm to 5.3 cm. Most common surgical procedure was medial maxillectomy (12 patients). Eight patients received chemotherapy, ten received radiotherapy and six received both. One third of patients received interferon-alpha. Median recurrence-free survival (RFS) was 14.4 months, with a 1-year RFS rate of 55%. Median overall survival (OS) was 19.3 months with a 1-year OS rate of 60% and a 2-year OS rate of 42%. The 5-year OS rate was 34%. CONCLUSION: SNMM remains a disease that has eluded breakthroughs in treatment. Patients are typically treated with wide local resection; however unique to our institution was the frequent use of interferon and chemoradiation. Further research in adjuvant therapies will be necessary to improve outcomes.
OBJECTIVE: Report the experience of the Karmanos Cancer Institute with sinonasal mucosal melanoma (SNMM) in patients diagnosed between 1995 and 2007. RESULTS: Eighteen patients, ages 31 to 85 (mean, 67), whose most common presenting symptoms included epistaxis and facial pressure. Most common anatomic locations were the maxillary sinus and nasal cavity. Seventy-two percent presented with tumors extending to the skull base, frontal sinus, orbit, or cranium. Tumor size ranged from 0.3 cm to 5.3 cm. Most common surgical procedure was medial maxillectomy (12 patients). Eight patients received chemotherapy, ten received radiotherapy and six received both. One third of patients received interferon-alpha. Median recurrence-free survival (RFS) was 14.4 months, with a 1-year RFS rate of 55%. Median overall survival (OS) was 19.3 months with a 1-year OS rate of 60% and a 2-year OS rate of 42%. The 5-year OS rate was 34%. CONCLUSION: SNMM remains a disease that has eluded breakthroughs in treatment. Patients are typically treated with wide local resection; however unique to our institution was the frequent use of interferon and chemoradiation. Further research in adjuvant therapies will be necessary to improve outcomes.
Authors: J M Kirkwood; J Ibrahim; D H Lawson; M B Atkins; S S Agarwala; K Collins; R Mascari; D M Morrissey; P B Chapman Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: B W Hancock; K Wheatley; S Harris; N Ives; G Harrison; J M Horsman; M R Middleton; N Thatcher; P C Lorigan; J R Marsden; L Burrows; M Gore Journal: J Clin Oncol Date: 2003-12-09 Impact factor: 44.544
Authors: Tyler P Robin; Bernard L Jones; Oren M Gordon; Andy Phan; Diana Abbott; Jessica D McDermott; Julie A Goddard; David Raben; Ryan M Lanning; Sana D Karam Journal: Cancer Date: 2017-04-03 Impact factor: 6.860
Authors: Fernando López; Juan P Rodrigo; Antonio Cardesa; Asterios Triantafyllou; Kenneth O Devaney; William M Mendenhall; Missak Haigentz; Primož Strojan; Phillip K Pellitteri; Carol R Bradford; Ashok R Shaha; Jennifer L Hunt; Remco de Bree; Robert P Takes; Alessandra Rinaldo; Alfio Ferlito Journal: Head Neck Date: 2015-05-22 Impact factor: 3.147
Authors: Ji-Jin Yao; Fan Zhang; Guang-Shun Zhang; Xiao-Wu Deng; Wang-Jian Zhang; Wayne R Lawrence; Lu Zou; Xiao-Shi Zhang; Li-Xia Lu Journal: Cancer Manag Res Date: 2018-12-14 Impact factor: 3.989
Authors: Piotr Rutkowski; Marcin Zdzienicki; Zbigniew I Nowecki; Alexander C J Van Akkooi Journal: Cancers (Basel) Date: 2010-05-11 Impact factor: 6.639
Authors: K Luna-Ortiz; M Aguilar-Romero; V Villavicencio-Valencia; E Zepeda-Castilla; H Vidrio-Morgado; N Peteuil; A Mosqueda-Taylor Journal: Med Oral Patol Oral Cir Bucal Date: 2016-07-01